The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients-Reference-Cited by-同舟云学术

The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients

Published:2016 Issue:3 Volume:57 Page:174
ISSN:2466-0493
Container-title:Investigative and Clinical Urology
language:en
Short-container-title:Investig Clin Urol

Author:

Kim Choung-Soo¹,Theeuwes Ad²,Kwon Dong Deuk³,Choi Young Deuk⁴,Chung Byung Ha⁵,Lee Hyun Moo⁶,Lee Kang Hyun⁷,Lee Sang Eun⁸

Affiliation:

1. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

2. Biostatistics, Astellas Pharma Europe B.V., Leiden, The Netherlands.

3. Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea.

4. Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.

5. Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

6. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

7. Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea.

8. Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea.

Publisher

The Korean Urological Association

Subject

Urology

Link

http://synapse.koreamed.org/pdf/10.4111/icu.2016.57.3.174

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran;BMC Urology;2024-02-20

2. Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus Without Confirmatory Bone Scan;Cancer Research and Treatment;2023-12-05

3. Enzalutamide in metastatic castration-resistant prostate cancer, real-world data;Medical Science and Discovery;2022-01-09

4. High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients;Cancers;2021-08-05

5. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial;International Journal of Clinical Oncology;2020-11-23